Precirix NV, a Belgian biotech company created in 2014 as a spin-off from the Vrije Universiteit Brussel, has raised €80 million in a Series B financing round to advance a pipeline of radiopharmaceuticals for cancer. The technology involves the use of antibody fragments derived from llama to transport radioisotopes to receptors on the surface of cancer cells and kill the cells by irradiation. The antibody fragments are similar to those used by Ablynx, now part of Sanofi SA, to successfully build a portfolio of products for rare diseases.
